Rook AH, Gelfand JC, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452-1461.

doi:10.1182/blood-2015-10-678938

On page 1452 in the 17 September 2015 issue, the second author’s middle initial is incorrect. The name Joel C. Gelfand should read Joel M. Gelfand. The error has been corrected in the online version, which now differs from the print version.

2015

Sign in via your Institution

Rook AH, Gelfand JC, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452-1461.

Cited By

Email alerts

ASH Publications

American Society of Hematology

Rook AH, Gelfand JC, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452-1461.

This feature is available to Subscribers Only

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only